Document Detail

Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs.
MedLine Citation:
PMID:  21359537     Owner:  NLM     Status:  MEDLINE    
PURPOSE: DRESS (drug reaction with eosinophilia and systemic symptoms) is an idiosyncratic entity associated with the use of drugs. Its pathophysiology is not known, but is associated with immunological or genetic factors. The incidence is 0.4 cases per 1,000,000 general population. The syndrome usually develops at the beginning of treatment and is characterized by the presence of rash, fever, eosinophilia and systemic manifestations. The aim of our study was to describe the clinical manifestation and treatment of patients with DRESS associated with antiepileptic drugs (AEDs).
METHODS: This is a descriptive study with the aim of describing the clinical manifestation and treatment associated with DRESS produced by aromatic and non-aromatic AEDs.
RESULTS: Eight patients treated with AEDs developed DRESS between January 2007 and May 2010 at our hospital. All had dermatological manifestations, eosinophilia and systemic (haematological and hepatic) manifestations that could be attributed to treatment with aromatic AEDs (carbamazepine, 2 patients; lamotrigine, 3 patients; phenytoin, 3 patients). Therapeutic management included removal of the drug from the therapeutic regime, symptomatic management, life support and use of corticosteroids. There was no mortality associated with the syndrome. Reversion of systemic manifestations was very slow: between 1 and 6 months.
CONCLUSIONS: DRESS is a severe cutaneous reaction, with high morbidity and mortality, whose development seems to be associated with individual susceptibility, type of antiepileptic drug used (more common with aromatic drugs), titration rate and concomitant medications.
Nahuel Pereira de Silva; Paulo Piquioni; Silvia Kochen; Patricia Saidon
Related Documents :
529027 - Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats.
24300917 - Clinical features of taxane neuropathy.
23644347 - Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects.
24267197 - Use of nsaids in treating patients with arthritis.
24339407 - Monovinyl sulfone β-cyclodextrin. a flexible drug carrier system.
22980497 - European drug reimbursement systems' legitimacy: five-country comparison and policy tool.
Publication Detail:
Type:  Journal Article     Date:  2011-02-26
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  67     ISSN:  1432-1041     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-04-14     Completed Date:  2011-08-10     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  463-70     Citation Subset:  IM    
Epilepsy Section, Neurology Division, José María Ramos Mejía Hospital, Urquiza 609 (1221), Buenos Aires, Argentina.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Hormones / therapeutic use
Anticonvulsants / adverse effects*,  therapeutic use
Carbamazepine / adverse effects,  therapeutic use
Disease Susceptibility
Drug Eruptions / etiology*,  therapy
Drug Hypersensitivity / etiology*,  therapy
Eosinophilia / chemically induced*,  therapy
Exanthema / chemically induced*,  therapy
Fever / chemically induced
Middle Aged
Phenytoin / adverse effects,  therapeutic use
Risk Factors
Triazines / adverse effects,  therapeutic use
Young Adult
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Anticonvulsants; 0/Triazines; 298-46-4/Carbamazepine; 57-41-0/Phenytoin; U3H27498KS/lamotrigine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver trans...
Next Document:  Cryoneurolysis for zygapophyseal joint pain: a retrospective analysis of 117 interventions.